Awakn Life Sciences

Awakn Life Sciences aims to bring psychedelics therapy to the UK. Under this company fall three arms; psychedelic research, clinic platform, and practitioner training.

Awakn Life Sciences

“Awakn is a UK and European focused company that is dedicated to integrating psychedelics into mental healthcare. We work across three business lines of clinical research, therapeutic clinics and practioner training.”

The three arms of the company are:


Awakn started in 2020 and announced itself by buying a controlling (51%) stake in Ben Sessa’s private practice (Mandela Therapy Limited).

You can read their July 2020 investor presentation here.

In June 2021, Awakn announced it completed a private placement for aggregate gross proceeds of $6.64 million US.

Awakn is listed on the NEO exchange under the ticker AWKN.

Many of the key staff (below) have come from the cannabis industry (US/CA).

In October 2021, Awakn Clinics Bristol (UK) received formal approval from the Care Quality Commission’s (CQC) to begin treating patients using ketamine-assisted therapy. Awakn currently operates a clinic in Oslo, Norway and are awaiting approval to begin treating patients from their London location.

Key Staff

  • David Nutt – Chairman, Scientific Advisory Board
  • Ben Sessa – Chief Medical Officer
  • George Scorsis – Chairman, Corporate Board
  • Anthony Tennyson – Chief Executive Officer
  • Jonathan Held – Chief Financial Officer
  • Laurie Higbed – Lead Pychologist
  • Dawn DeCunha – Advisor
  • Mike Hart – Advisor
  • Matthew Johnson – Scientific Advisory Board


Although AWAKN will most probably work with universities for their research, currently they don’t list partners.


Company Information

Awakn Life Sciences Website

June, 2020


B2C Pharmaceutical Clinic

Topics of Interest
Alcohol Use Disorder Addiction

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

Awakn Successfully Completes Phase One Of Its Drug Discovery Program (Awakn Life Sciences, 06 April 2022)

Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder (Awakn Life Sciences, 02 June 2022)

Awakn Life Sciences Appoints Uk Leader In Addictions Psychiatry, Dr. Arun Dhandayudham, As Chief Medical Officer (Awakn Life Sciences, 17 May 2022)

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)
This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments (Biospace, 17 March 2022)

Awakn Life Sciences Announces Closing of Private Placement (Bloomberg, 22 March 2022)

Awakn CEO on Addiction: ‘The Biggest Unmet Medical Need of Modern Times’ (The Dales Report, 24 March 2022)

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK (, 16 November 2021)


HQ / Office 1 Regent St, Clifton, Bristol BS8 4HW, UK
HQ / Office 366 Bay St., Toronto, ON M5H 4B2, Canada